Treace Medical Concepts, Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 6, 2025 and accepted by EDGAR at Nov 6, 2025, 16:14 ET.
Management's discussion and analysis
As filed, 43,249 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes thereto included in this Quarterly Report on Form 10-Q (this "Quarterly Report") and our audited financial statements and related notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on February 27, 2025 (our "Annual Report"). This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report under "Part I, Item 1A–Risk Factors," and in the section titled "Risk Factors" and elsewhere in this Quarterly Report. Please also see the section of this Quarterly Report titled "Special Note Regarding Forward-Looking Statements."
Overview
We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. We have pioneered our proprietary Lapiplasty® 3D Bunion Correction System®–a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensional ("3D") misalignment in the foot's anatomical structure, the majority of traditional surgical approaches focus on correcting the deformity from a two-dimensional ("2D") perspective and therefore fail to address the root cause of the disorder. To effectively restore the normal anatomy of bunion patients and improve clinical outcomes, we believe addressing the root cause of the bunion is critical, and have developed the Lapiplasty System to correct the deformity across all three anatomic dimensions. Our other products often used in conjunction with bunion surgery include the Adductoplasty® System, the Hammertoe PEEK Fixation System, the SpeedPlate® Rapid Compression Implant System, and specialized osteotomes and release instruments. In addition, we recently entered the metatarsal osteotomy segment with the Nanoplasty® and Percuplasty™ Procedures, which both allow for a 3D correction of the bunion through cosmetically appealing, minimally invasive solutions. With our Lapiplasty System, new osteotomy systems, and other complementary products, we are continuing to execute our strategy of becoming a comprehensive bunion solutions company and supporting further penetration into the bunion market opportunity. See the "Innovation and Growth" section below for more information on our new products.
We were formed in 2013, and since receiving 510(k) clearance for the Lapiplasty System in March 2015, we have expanded our bunion related products in the United States. We market and sell our products to surgeons, ambulatory surgery centers, hospitals, and stocking distributors. As part of our strategy for 2025, we began utilizing a limited number of stocking distributors in the first quarter of 2025. Our procedures can be performed in either hospital outpatient or ambulatory surgery center settings, and utilize existing, well-established reimbursement codes. We primarily market and sell our products through a combination of a direct employee sales force and independent sales agencies in the United States.
As of September 30, 2025, we had cash and cash equivalents of $7.7 million and marketable securities of $49.7 million available for sale to fund operations, an accumulated deficit of $239.6 million and $54.0 million of principal outstanding under our term loan and revolving loan agreements.
Economic Environment
The economy is expected to slow in the remainder of 2025 and 2026 amid continuing macroeconomic uncertainty. Inflation, recession fears, reduced consumer confidence, higher insurance deductibles and other costs, and other adverse economic conditions have and may continue to negatively impact consumer demand for our products that are used in elective surgeries. While we continuously work with suppliers to mitigate higher costs and continue to invest in our direct sales channel, patient education initiatives, clinical evidence and product innovations to build demand for our products, we expect these macroeconomic challenges to continue for the foreseeable future, which likely will impact the demand for our products and our results of operations. Adding to these uncertainties are the protracted government shutdown and evolving U.S. tariff policies on imports, along with retaliatory tariffs, that may change rapidly. While we expect that the tariffs are likely to increase our inventory costs and reduce gross margins, we do not expect these impacts to be material at the most recently announced tariff rates.
Increased Competition
Before we launched our flagship Lapiplasty System, there were no other products in the market that provided a 3D solution and specialized procedural instrumentation for traditionally freehand, difficult Lapidus surgeries. This allowed us to capitalize on our pioneering technology and grow our market share quickly. We are experiencing increased competition from the accelerating adoption of minimally invasive osteotomy solutions and from new Lapidus products, which has, and may continue to, negatively impact our growth rates, market share, and results of operations. In order to drive increased penetration into the bunion market, we have introduced new bunion systems, including two minimally invasive osteotomy systems and a great toe fusion system. While the adoption of these new systems is increasing, we generally sell them at lower average selling prices than our Lapiplasty System. To the extent we lose market share or experience further declines in sales of our Lapiplasty System and we are unable to sufficiently increase sales of our new bunion systems to offset the declines in sales of our Lapiplasty System, our revenues and results of operations will be adversely affected.
Innovation and Growth
We expect to continue to focus on long-term revenue growth through investments in our business and new products. In sales and marketing, we have dedicated meaningful resources to building a sales force and management team to support our future growth and to providing bunion-focused surgeon training and patient-focused outreach and education.
In research and development, our employee team and surgeon consultants are continually working on next-generation innovations for the surgical correction of bunions and other conditions that often present with bunions. In the fourth quarter of 2024, we began the limited market releases of the following new products: (1) the Nanoplasty and Percuplasty Systems, which are minimally-invasive 3D osteotomy systems; (2) IntelliGuide™ PSI Cut Guides for Lapiplasty and Adductoplasty Procedures, which are cut guides created specifically for an individual patient’s foot anatomy; (3) the Micro-Lapiplasty® System, which is designed to allow the Lapiplasty Procedure to be performed through a minimally-invasive 2cm incision; (4) the Mini-Adductoplasty™ System, which is designed to allow the Adductoplasty midfoot correction procedure to be performed through an approximately 50% smaller incision; and (5) the SpeedMTP® Rapid Compression Implant, a specialized implant for addressing bunions through MTP fusions. In the first half of 2025, we began the limited market release of the SpeedAkin™ implant used in Akin osteotomy procedures, the SpeedPlate Micro-Quad implant, and four new single use osteotomes. We have continued to expand the commercial availability of these new products and to release other new solutions during 2025, including the Percuplasty™ MIS Power System, a specialized and scalable power drill that operates the single-use cutting burrs used in the Percuplasty™ procedure as well as other minimally invasive procedures throughout the foot, and biologics commonly used in foot and ankle fusion procedures. We plan to begin offering additional innovations in 2026, including the Lapiplasty Lightning platform designed to further increase the precision and speed of the Lapiplasty 3D correction, a new line of compression screws, and additional procedure specific SpeedPlate implants and sterile instruments.
Intellectual Property Strategy
We actively seek to protect the technology, inventions, and improvements that we consider important to our business using patents, trade secrets, trademarks and copyrights in the United States and foreign markets. As of September 30, 2025, our patent portfolio included 90 granted U.S. patents, with an additional 31 granted patents worldwide and over 175 pending patent applications. In keeping with our strategy of protecting our intellectual property rights, on October 14, 2024, we filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") alleging infringement of 9 patents related to our innovative Lapiplasty 3D Bunion Correction technologies and unfair competition. The suit was filed in the United States District Court for the District of New Jersey, and seeks injunctive relief and damages. In addition, on May 12, 2025, we filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "ZB") alleging infringement of 4 patents related to our innovative Lapiplasty 3D Bunion Correction technologies. The suit was filed in the United States District Court for the District of Delaware and seeks injunctive relief and damages. On August 5, 2025, we filed an amended complaint alleging infringement of an additional patent.
Market Share Growth
The growth of our business depends on our ability to gain broader acceptance of our proprietary procedures and systems by successfully marketing and distributing these products. While surgeon adoption of our products and procedures remains critical to supporting revenue growth, hospital and ambulatory surgery center facility approvals are necessary for existing and future surgeon customers to access our products. To facilitate greater access to our products and support future sales growth, we intend to continue educating hospitals and facility administrators on the differentiated benefits associated with our procedures and systems, supported by our robust portfolio of clinical data on our existing procedures and additional clinical data we expect to develop on our new products. To continue to build our market share, in 2025, we have added new commercial and sales leadership as well as experienced foot and ankle sales professionals to our team. While we have experienced overall increases in bunion procedure kit sales and in our market share, our flagship Lapiplasty System is expected to contribute less to our market share growth in future quarters, which could result in reduced revenues and impact our liquidity if product sales from our new bunion systems do not increase sufficiently to offset the decline in sales of the Lapiplasty System. If we are unable to successfully continue to commercialize our procedures and systems, we may not be able to generate sufficient revenue to achieve or sustain profitability. In the near term, we expect we will continue to operate at a loss, and we anticipate we will finance our operations principally through the use of our cash and cash equivalents, marketable securities, and expected revenues. We may also raise funds by incurring debt and through offerings of our capital stock.
Seasonality
We have experienced and expect to continue to experience seasonality in our business, with higher sales volumes in the fourth calendar quarter, historically accounting for approximately 30% to 40% of full year revenues, and lower sales volumes in the subsequent first calendar quarter. Our sales volumes in the fourth quarter tend to be higher as many patients elect to have surgery after meeting their annual deductible and having time to recover over the winter holidays. Our sales volumes in subsequent first calendar quarters also tend to be lower versus the prior year fourth quarters as a result of adverse weather and by resetting annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures; however, in some years the first quarter may benefit from additional sales volumes when high patient demand for surgeries in the fourth quarter cannot be fully accommodated and those surgical procedures are rolled over into the first quarter. In addition to the seasonality noted above, we generally expect lower sales volumes in the second and third quarters than throughout the rest of the year as elective procedures generally decline during the spring and summer months.
Coverage and Reimbursement
Hospitals, ambulatory surgery centers and surgeons that purchase or use our products generally rely on third-party payors to reimburse for all or part of the costs and fees associated with procedures using our products. As a result, sales of our products depend, in part, on the extent to which the procedures using our products are covered by third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs. Based on historical claims data, more than 60% of all bunion surgical cases are paid by private payors.
Medicare payment rates to hospital outpatient departments are set under the Medicare hospital outpatient prospective payment system, which groups clinically similar hospital outpatient procedures and services with similar costs to ambulatory payment classifications ("APCs"). Each APC is assigned a single lump sum payment rate, which includes payment for the primary procedure as well as any integral, ancillary, and adjunctive services. The primary current procedure terminology ("CPT") codes for the Lapiplasty Procedure, CPT 28297 and CPT 28740, are grouped together under APC 5114. For Lapiplasty Procedures in which fusion is performed on multiple tarsometatarsal ("TMT") joints, CPT 28730 applies and is classified under APC 5115. For Adductoplasty Procedures in which fusion is performed on multiple TMT joints, either CPT 28730 or CPT 27835 applies and are classified under APC 5115. For the Nanoplasty and Percuplasty Procedures, CPT 28306 applies. For MTP fusions using the SpeedMTP implant or our other plates, CPT 28750 applies.
Components of Our Results of Operations
Revenue
We currently generate revenue from the sale of our bunion implant kit systems, single-use sterile instruments, and other complementary products. Our systems bring together single-use implant kits, reusable instrument trays, and surgical techniques. We sell the kits and single-use instruments and other products to hospitals, ambulatory surgery centers, and stocking distributors in the United States through a network of employee sales representatives and independent sales agencies.
No single customer accounted for 10% or more of our revenue during the nine months ended September 30, 2025. We expect our revenue to increase in absolute dollars in the foreseeable future as we expand our product offerings, new accounts and trained physician base, and as existing physician customers that use our products perform more procedures using our products, although our rate of revenue growth may fluctuate from quarter to quarter due to a variety of factors, including seasonality, the macroeconomic environment and competition.
Cost of Goods Sold
Cost of goods sold consists primarily of direct costs for the purchase of our products from third-party manufacturers. Cost of goods sold also includes royalties, overhead, shipping costs, sterilization, and packaging. We expense all inventory provisions for excess, obsolete, and field losses as cost of goods sold. We evaluate the carrying value of our inventories in relation to historical sales, current inventory levels, and consideration of the life cycle of the product. A significant decrease in demand or development of products could result in an increase in the amount of excess or obsolete inventory on hand, which could lead to additional provisions. We expect our cost of goods sold to increase in absolute dollars in the foreseeable future to the extent more of our products are sold, though it may fluctuate from quarter to quarter.
Gross Profit and Gross Margin
We calculate gross profit as revenue less cost of goods sold, and gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily average selling prices, production, and ordering volumes, change in mix of customers, third-party manufacturing costs and cost-reduction strategies. We expect our gross profit to increase in the foreseeable future as our revenue grows, though our gross margin may fluctuate from quarter to quarter due to changes in average selling prices as we introduce new products, and as we adopt new manufacturing processes and technologies.
Operating Expenses
Sales and Marketing
Sales and marketing expenses consist primarily of compensation for personnel, including salaries, bonuses, benefits, sales commissions and share-based compensation, related to selling and marketing functions, surgical instrument expense, physician education programs, training, shipping costs related to sending products to our sales representatives, travel expenses, marketing initiatives including our direct-to-consumer outreach program and advertising, market research and analysis and conferences and trade shows.
Research and Development
Research and development ("R&D") expenses consist primarily of engineering, product development, clinical studies to develop and support our products, regulatory expenses, and other costs associated with products and technologies that are in development. These expenses include compensation for personnel, including salaries, bonuses, benefits and share-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation, and allocated facilities-related expenses.
General and Administrative
General and administrative expenses consist primarily of compensation for personnel, including salaries, bonuses, benefits, and share-based compensation, related to finance, information technology, legal and human resource functions, as well as professional services fees (including legal, audit and tax fees), insurance costs, general corporate expenses, and allocated facilities-related expenses.
Interest Income
Interest income consists of interest received on our money market funds and marketable securities.
Interest Expense
Interest expense consists of interest incurred and amortization of debt discount and issuance costs related to outstanding borrowings.
Results of Operations
Comparison of the three and nine months ended September 30, 2025 and 2024
The following table summarizes our results of operations for the periods presented below ($ in thousands):
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | Nine Months Ended September 30, 2025 | 2024 | Change Amount% | |||
|---|---|---|---|---|---|---|---|---|
| Revenue | $50,214 | $45,086 | $5,128 | 11.4% | $150,171 | $140,649 | $9,522 | 6.8% |
| Cost of goods sold | 10,508 | 8,954 | 1,554 | 17.4% | 30,820 | 27,862 | 2,958 | 10.6% |
| Gross profit | 39,706 | 36,132 | 3,574 | 9.9% | 119,351 | 112,787 | 6,564 | 5.8% |
| Operating expenses | ||||||||
| Sales and marketing | 34,421 | 32,775 | 1,646 | 5.0% | 103,627 | 110,784 | (7,157) | (6.5)% |
| Research and development | 4,680 | 4,963 | (283) | (5.7)% | 15,740 | 15,379 | 361 | 2.3% |
| General and administrative | 16,281 | 13,528 | 2,753 | 20.4% | 48,216 | 42,108 | 6,108 | 14.5% |
| Total operating expenses | 55,382 | 51,266 | 4,116 | 8.0% | 167,583 | 168,271 | (688) | (0.4)% |
| Loss from operations | (15,676) | (15,134) | (542) | 3.6% | (48,232) | (55,484) | 7,252 | (13.1)% |
| Interest income | 634 | 1,067 | (433) | (40.6)% | 2,250 | 3,978 | (1,728) | (43.4)% |
| Interest expense | (1,338) | (1,313) | (25) | 1.9% | (3,970) | (3,942) | (28) | 0.7% |
| Other income, net | 92 | 20 | 72 | *% | 344 | 206 | 138 | 67.0% |
| Other non-operating income (expense), net | (612) | (226) | (386) | 170.8% | (1,376) | 242 | (1,618) | *% |
| Net loss | $(16,288) | $(15,360) | $(928) | 6.0% | $(49,608) | $(55,242) | $5,634 | (10.2)% |
* Not meaningful
Comparison of the three months ended September 30, 2025 and 2024
Revenue. Revenue increased by $5.1 million, or 11.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily driven by an increase in the number of bunion procedure kits sold, partially offset by lower average selling prices of our newest bunion procedure kits. While the number of bunion procedure kits sold are increasing overall, our flagship Lapiplasty System is experiencing lower sales primarily due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery due to macroeconomic conditions. Revenue for the three months ended September 30, 2025 included $6.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders, compared to no stocking distributor sales during the same period in 2024. As of the end of third quarter, our stocking distributors have purchased their initial stock of inventory; therefore, we do not expect sales at this level in future quarters.
Cost of Goods Sold, Gross Profit and Gross Margin. Cost of goods sold increased by $1.6 million, or 17.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in cost of goods sold was primarily due to a $1.2 million increase in direct cost of goods sold resulting from increased sales. During the three months ended September 30, 2025, gross profit increased by $3.6 million, or 9.9%, as compared to the same period in 2024, due to increased sales. Gross profit margin for the three months ended September 30, 2025 decreased from 80.1% to 79.1%, as compared to the same period in 2024, primarily due to lower margin sales to stocking distributors, partially offset by a shift in product mix.
Sales and Marketing Expenses. Sales and marketing expenses increased by $1.6 million, or 5.0%, for the three months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses increased due to a $1.2 million increase in commissions, a $0.5 million increase in surgical instrument expense from higher volume of surgical instruments, a $0.4 million increase in payroll and related costs, a $0.4 million increase for surgeon training and clinical-related expenses, and a $0.2 million increase from higher costs for conferences and events, partially offset by a $1.3 million decrease in direct to consumer advertising costs. Of the $0.4 million increase in payroll and related costs, $1.0 million was related to a non-recurring restructuring charge that includes severance and other post-employment benefits, partially offset by a decrease in other payroll-related costs.
Research and Development Expenses. R&D expenses decreased by $0.3 million, or 5.7%, for the three months ended September 30, 2025 as compared to the same period in 2024. The decrease in R&D expenses was primarily due to a $0.2 million decrease in purchases of prototypes.
General and Administrative Expenses. General and administrative expenses increased by $2.8 million, or 20.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in general and administrative expenses was due to a $2.9 million increase in legal fees primarily driven by ongoing litigation matters, partially offset by a $0.2 million decrease in the provision for allowance for credit losses.
Interest Income. Interest income decreased $0.4 million, or 40.6%, for the three months ended September 30, 2025 as compared to the same period in 2024. The decrease in interest income was primarily due to lower balances invested in marketable securities during the current year period.
Comparison of the nine months ended September 30, 2025 and 2024
Revenue. Revenue increased by $9.5 million, or 6.8%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily driven by an increase in the number of bunion procedure kits sold, partially offset by lower average selling prices of our newest bunion procedure kits. While the number of bunion procedure kits sold are increasing overall, our flagship Lapiplasty System is experiencing lower sales primarily due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery related to macroeconomic conditions. Revenue for the nine months ended September 30, 2025 included $11.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders, compared to no stocking distributor sales during the same period in 2024. As of the third quarter, our stocking distributors have purchased their initial stock of inventory; therefore, we do not expect sales at the level experienced during the third quarter of 2025 in future quarters.
Cost of Goods Sold, Gross Profit and Gross Margin. Cost of goods sold increased by $3.0 million, or 10.6%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in cost of goods sold was primarily due to a $1.7 million increase in direct costs of goods sold resulting from increased sales and a $1.1 million increase in inventory provisions. During the nine months ended September 30, 2025, gross profit increased by $6.6 million, or 5.8%, as compared to the same period in 2024, due to increased sales. Gross profit margin for the nine months ended September 30, 2025 decreased from 80.2% to 79.5%, as compared to the same period in 2024, primarily due to lower margin sales to stocking distributors and increases in inventory provisions, partially offset by a shift in product mix.
Sales and Marketing Expenses. Sales and marketing expenses decreased by $7.2 million, or 6.5%, for the nine months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses decreased due to a $7.6 million reduction in direct to consumer advertising costs and a $6.0 million decrease in payroll and related costs primarily from optimizing the size and structure of our direct employee sales force, partially offset by a $2.7 million increase for surgeon training and clinical-related expenses, a $1.7 million increase in commissions, and a $1.4 million increase in surgical instrument expense from higher volume of surgical instruments.
Research and Development Expenses. R&D expenses increased by $0.4 million, or 2.3%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in R&D expenses was primarily due to a $0.9 million increase in payroll and related costs resulting from increased headcount of R&D personnel, partially offset by a $0.5 million decrease in compensation expense related to the milestone obligation for our acquisition of MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D") that was incurred in the nine months ended September 30, 2024, but not in the nine months ended September 30, 2025.
General and Administrative Expenses. General and administrative expenses increased by $6.1 million, or 14.5%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in general and administrative expenses was due to a $4.9 million increase in payroll and related costs, including stock compensation expense, and a $3.6 million increase in legal fees primarily driven by ongoing litigation matters, partially offset by a $1.9 million decrease in the provision for allowance for credit losses as compared to the second quarter of 2024 that included a $2.1 million write-off of receivables due from a customer that filed bankruptcy in the second quarter of 2024 and a decrease of $1.3 million in compensation expense related to the milestone obligation for our acquisition of RPM-3D that was incurred in the nine months ended September 30, 2024 but not in the nine months ended September 30, 2025.
Interest Income. Interest income decreased $1.7 million, or 43.4%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The decrease in interest income was primarily due to lower balances invested in marketable securities during the current year period.
Liquidity and Capital Resources
Overview
Before our initial public offering ("IPO"), our primary sources of capital were private placements of common stock and convertible preferred stock, debt financing agreements and revenue from the sale of our products. In April 2021, we received net proceeds of $107.6 million from our IPO. On February 10, 2023, we received net proceeds of $107.5 million from a follow-on public offering of our common stock.
As of September 30, 2025, we had cash and cash equivalents of $7.7 million and marketable securities of $49.7 million available for sale, an accumulated deficit of $239.6 million and $54.0 million of principal outstanding under our term loan and revolving loan agreements. We believe that our existing cash and cash equivalents, marketable securities, available debt borrowings and expected revenues will be sufficient to meet our capital requirements and fund our operations for at least twelve months from the date of issuance of these condensed financial statements. We may be required or decide to raise additional debt or equity financing to support further growth of our operations.
Funding Requirements
We use our cash, marketable securities, and revenues to fund our operations, which primarily include the costs of manufacturing our products, capital expenditures, as well as our operating expenses. We expect R&D expenses to increase as we continue to hire personnel and invest in next-generation innovations of our existing products and new products. The timing and amount of our operating and capital expenditures and use of available funding will depend on many factors, including:
- the scope and timing of our investment in our commercial infrastructure and sales force;
- the costs of our ongoing commercialization activities including product sales, marketing, manufacturing, and distribution;
- the scope of our marketing efforts, including the degree to which we utilize direct to consumer campaigns;
- the degree and rate of market acceptance of our products;
- the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, including enforcing our intellectual property rights against infringing products or technologies or enforcing contractual rights against parties breaching agreements with us, including the litigation proceeding we initiated against Stryker and ZB;
- the research and development activities we intend to undertake to improve the Lapiplasty System and other products, to commercialize PSI technologies, to gain share in the minimally invasive osteotomy market, and to develop or acquire additional products;
- the investments we make in acquiring other technologies, assets or businesses to expand our product portfolio;
- the success or emergence of new competing technologies or other adverse market developments;
- our need to implement additional infrastructure and internal systems;
- competitors' success in inducing surgical facilities to limit their use of our products and surgical facilities' decisions to narrow surgeons' access to our products;
- the effect of inflation, interest rate changes, evolving or increased tariffs, changes in trade policy or global trade disruptions and other general economic conditions on our operations and business;
- the ability of customers to pay us for our products, including stocking distributors which generally have longer payment terms than hospital and ambulatory surgery center customers;
- any product liability or other lawsuits related to our products;
- the expenses needed to attract and retain skilled personnel; and
- the impact of any infectious disease outbreak or natural or other disaster or event beyond our control on our business or on the healthcare industry, particularly elective surgeries where our products are used.
Based upon our current operating plan, we believe that our existing cash, cash equivalents, marketable securities, and available debt borrowings will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong or that may change in the future, and we could utilize our available capital resources sooner than we expect. We may seek to raise any necessary additional capital through public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these or other funding sources. Additional funds may not be available to us on acceptable terms or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, we could be forced to delay, limit, reduce or terminate our product development programs, commercialization efforts, sales and marketing initiatives, or other operations. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to provide additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.
Cash Flows
The following table sets forth the primary sources and uses of cash and cash equivalents for the periods presented below (in thousands):
| Net cash (used in) provided by: | Nine Months Ended September 30, 2025 | 2024 |
|---|---|---|
| Operating activities | $(7,944) | $(32,960) |
| Investing activities | 3,585 | 31,954 |
| Financing activities | 695 | 134 |
| Net increase (decrease) in cash and cash equivalents | $(3,664) | $(872) |
Cash Flows from Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2025 was $7.9 million, consisting primarily of a net loss of $49.6 million, adjusted for non-cash charges of $37.1 million and a decrease in net operating assets. The non-cash charges consist primarily of $26.3 million in share-based compensation expense, $7.8 million in depreciation and amortization, $1.7 million in non-cash lease expense, and $0.5 million in provision for allowance for credit losses. The decrease in net operating assets was primarily due to a $7.4 million decrease in accounts receivable from collection on higher sales in the fourth quarter of 2024 and a $5.6 million increase in accounts payable due to timing of payments, partially offset by a $2.4 million decrease in operating lease liabilities, a $3.2 million decrease in accrued liabilities, and a $2.2 million increase in inventory. The decrease in accrued liabilities was primarily from a decrease in accrued commissions from lower sales in the third quarter of 2025 compared to the fourth quarter of 2024, partially offset by increased accrued compensation from timing of payroll and a non-recurring restructuring charge that includes severance and other post-employment benefits.
Net cash used in operating activities for the nine months ended September 30, 2024 was $33.0 million, consisting primarily of a net loss of $55.2 million, adjusted for non-cash charges of $30.6 million and an increase in net operating assets. The non-cash charges consist primarily of $22.0 million in share-based compensation expense, $6.2 million in depreciation and amortization expense, and $2.4 million in provision for allowance for credit losses, primarily due to a significant customer that filed for bankruptcy. The increase in net operating assets was primarily due to a $14.4 million increase in inventories to meet demand for new products and a $12.8 million decrease in accrued liabilities due to timing of payments, and a $0.3 million increase in other non-current assets, partially offset by a $11.5 million decrease in accounts receivable from higher sales in the fourth quarter of 2023, a $6.8 million increase in accounts payable due to timing of payments, and a $0.8 million decrease in prepaid expenses and other current assets.
Cash Flows from Investing Activities
Net cash provided by investing activities was $3.6 million for the nine months ended September 30, 2025, consisting primarily of $49.6 million in sales and maturities of available-for-sale marketable securities, partially offset by $34.9 million in purchases of available-for-sale marketable securities and $11.1 million in purchases of property and equipment. The net cash generated from marketable securities sales and maturities and purchases of $14.7 million were primarily used to fund our current operations. The purchases in property and equipment included $9.4 million in capitalized surgical instruments for the reusable instrument trays related to our new products, and $1.6 million primarily for equipment, software, and leasehold improvements, to support the growth of our business.
Net cash provided by investing activities was $32.0 million for the nine months ended September 30, 2024, consisting primarily of $93.4 million in sales and maturities of available for sale marketable securities, partially offset by $52.9 million in purchases of available for sale marketable securities and $8.5 million in purchases of property and equipment. The net of marketable securities sales and maturities and purchases of $40.5 million were primarily used to fund our current operations. The purchases in property and equipment included $6.7 million in capitalized surgical instruments for the reusable instrument
trays related to new products, and $1.8 million for equipment and leasehold improvements to support the growth of our business.
Cash Flows from Financing Activities
Net cash provided by financing activities was $0.7 million for the nine months ended September 30, 2025, consisting primarily of $1.6 million in proceeds from insurance premium financing and $0.5 million in proceeds from stock option exercises, partially offset by $0.8 million of shares repurchased for tax withholding on vested RSUs and $0.5 million in payments on insurance premium financing.
Net cash provided by financing activities was $0.1 million for the nine months ended September 30, 2024, consisting primarily of $0.4 million in proceeds from stock option exercises, partially offset by $0.2 million of shares repurchased for tax withholding on vested RSUs.
Royalty Agreements
We recognized royalty expense of $1.6 million and $1.4 million for the three months ended September 30, 2025 and 2024, respectively. For the three months ended September 30, 2025 and 2024, the aggregate royalty rate was 3.1% and 3.2%, respectively. We recognized royalty expense of $4.7 million and $4.6 million for the nine months ended September 30, 2025 and 2024, respectively. For the nine months ended September 30, 2025 and 2024, the aggregate royalty rate was 3.1% and 3.3%, respectively. Each of the royalty agreements with our surgeon consultants prohibits the payment of royalties on products sold to entities and/or individuals with whom any of the surgeon consultants is affiliated.
Operating Lease
We have commitments for future payments related to our corporate headquarters office located in Ponte Vedra, Florida. We entered into a 10-year lease in February 2022 for our headquarters which expires in July 2032. Lease payments comprise the base rent plus operating costs which include taxes, insurance, and common area maintenance. We also have commitments for future payments related to our former headquarters which expire in April 2026 and have subleased this space for the remainder of our lease term. The remaining lease obligations are $20.8 million under these leases as of September 30, 2025.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of the condensed financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.
Goodwill
Our annual impairment testing date was July 1, 2025. We determined after performing the qualitative analysis that there was no evidence that it is more likely than not that the fair value of goodwill was less than the carrying amount. Therefore, it was not necessary to perform a quantitative impairment test. As of September 30, 2025 and December 31, 2024, goodwill was $12.8 million.
Our critical accounting policies and estimates are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations–Critical Accounting Policies and Estimates" in our Annual Report. There were no material changes to these accounting policies during the nine months ended September 30, 2025.
Recently Issued Accounting Pronouncements
Refer to Note 3, "Recent Accounting Pronouncements," of the Notes to Condensed Financial Statements for new accounting pronouncements not yet adopted as of this Quarterly Report.
Market risk
As filed, 210 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Market Risk
There have been no material changes from the market risk information previously disclosed in our Annual Report under "Part II–Item 7A. Quantitative and Qualitative Disclosures About Market Risk."
Controls and procedures
As filed, 3,148 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures
Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent limitation on the effectiveness of internal control
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Risk factors
As filed, 228 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K under "Part I, Item 1A–Risk Factors" for the year ended December 31, 2024, filed with the SEC on February 27, 2025.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $50.2m | us-gaap:Revenues |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $150.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $10.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $30.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $39.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $119.4m | us-gaap:GrossProfit |
| Research and development | 3 months2025-07-01 to 2025-09-30 | $4.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $15.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$15.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$48.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-07-01 to 2025-09-30 | $1.3m | us-gaap:InterestExpense |
| Interest expense | 9 months2025-01-01 to 2025-09-30 | $4.0m | us-gaap:InterestExpense |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$16.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$49.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 63,515,372 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 63,069,810 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | −$7.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-01-01 to 2025-09-30 | $11.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-09-30 | $7.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $138.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $196.6m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $40.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $107.4m | us-gaap:Liabilities |
| Long-term debt | At period end2025-09-30 | $53.5m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2025-09-30 | $1.8m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-09-30 | $89.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-25-269556. Last ingested by Listed: Nov 6, 2026, 11:57 ET. Listed shows no prices and gives no investment advice.